Newer Beta-lactam Antibiotics: Doripenem, Ceftobiprole, Ceftaroline, and Cefepime

Infectious Disease Clinics of North America

Volumn 23, Issue 4, 2009, Pages 983-996

  Bazan, Jose A ^a   Martin, Stanley I ^a   Kaye, Kenneth M ^b  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b CHANNING LABORATORY   (United States)

Author keywords

Beta lactam; Cefepime; Ceftaroline; Ceftobiprole; Doripenem

Indexed keywords

AMIKACIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE AMPC; CARBAPENEM DERIVATIVE; CEFEPIME; CEFTAROLINE; CEFTAROLINE FOSAMIL; CEFTAZIDIME; CEFTOBIPROLE; CEFTOBIPROLE MEDOCARIL; CEFTRIAXONE; CILASTATIN PLUS IMIPENEM; COTRIMOXAZOLE; DAPTOMYCIN; DORIPENEM; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; OXACILLIN; PENICILLINASE; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; RO 5788; UNCLASSIFIED DRUG; VANCOMYCIN;

ABDOMINAL INFECTION; ANTIBIOTIC RESISTANCE; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERIAL MENINGITIS; BONE INFECTION; BRAIN DISEASE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CREATINE KINASE BLOOD LEVEL; CRYSTALLURIA; DIABETIC FOOT; DIARRHEA; DOSE KIDNEY FUNCTION RELATION; DOSE TIME EFFECT RELATION; DRUG ANTAGONISM; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOCARDITIS; FEBRILE NEUTROPENIA; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; GRAM POSITIVE BACTERIUM; HEADACHE; HOSPITAL INFECTION; HUMAN; INFECTIOUS ARTHRITIS; LUNG INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MYOCLONUS; NAUSEA; NEUROTOXICITY; NONHUMAN; OSTEOMYELITIS; PHLEBITIS; PNEUMONIA; PRURITUS; RASH; RECOMMENDED DRUG DOSE; REVIEW; SEIZURE; SIDE EFFECT; SKIN INFECTION; SOFT TISSUE INFECTION; TASTE DISORDER; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA; VOMITING;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; BETA-LACTAMS; HUMANS;

EID: 70350705731     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2009.06.007     Document Type: Review

References (77)

1. Ortho-McNeil Pharmaceutical. Doribax (doripenem) package insert (2007), Ortho-McNeil Pharmaceutical, Raritan (NJ)
2. Davies T., Shang W., Bush K., et al. Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. Antimicrob Agents Chemother 52 (2008) 1510-1512
3. Bhavnani S.M., Hammel J.P., Cirincione B.B., et al. Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem. Antimicrob Agents Chemother 49 (2005) 3944-3947
4. Iso Y., Irie T., Nishino Y., et al. A novel 1 ß-methylcarbapenem antibiotic, S-4661. Synthesis and structure-activity relationships of 2-(5-substituted pyrrolidin-3-ylthio)-1 ß-methylcarbapenems. J Antibiot 49 (1996) 199-209
5. Rogers J.D., Meisinger M.A., Ferber F., et al. Pharmacokinetics of imipenem and cilastatin in volunteers. Rev Infect Dis 7 Suppl 3 (1985) S435-S446
6. Moon Y.S.K., Chung K.C., and Gill M.A. Pharmacokinetics of meropenem in animals, healthy volunteers, and patients. Clin Infect Dis 24 Suppl 2 (1997) S249-S255
7. Greer N.D. Doripenem (Doribax): the newest addition to the carbapenems. Proc (Bayl Univ Med Cent) 21 (2008) 337-341
8. Cirillo I., Mannens G., Janssen C., et al. The disposition, metabolism, and excretion of 14C-doripenem after a single 500-mg intravenous infusion in healthy men. Antimicrob Agents Chemother 52 (2008) 3478-3483
9. Lister P.D. Carbapenems in the USA: focus on doripenem. Expert Rev Anti Infect Ther 5 (2007) 793-809
10. Fritsche T.R., Stilwell M.G., and Jones R.N. Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003). Clin Microbiol Infect 11 (2005) 974-984
11. Ge Y., Wikler M.A., Sahm D.F., et al. In vitro antimicrobial activity of doripenem, a new carbapenem. Antimicrob Agents Chemother 48 (2004) 1384-1396
12. Tsuji M., Ishii Y., Ohno A., et al. In vitro and in vivo antibacterial activities of S-4661, a new carbapenem. Antimicrob Agents Chemother 42 (1998) 94-99
13. Jones R.N., Huynh H.K., Biedenbach D.J., et al. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. J Antimicrob Chemother 54 (2004) 144-154
14. Jones R.N., Huynh H.K., and Biedenbach D.J. Activities of doripenem (S-4661) against drug-resistant clinical pathogens. Antimicrob Agents Chemother 48 (2004) 3136-3140
15. Wexler H.M., Engel A.E., Glass D., et al. In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates. Antimicrob Agents Chemother 49 (2005) 4413-4417
16. Mushtaq S., Ge Y., and Livermore D.M. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob Agents Chemother 48 (2004) 3086-3092
17. Sakyo S., Tomita H., Tanimoto K., et al. Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa. J Antibiot (Tokyo) 59 (2006) 220-228
18. Kohler T., Michea-Hamzehpour M., Epp S.F., et al. Carbapenem activities against Pseudomonas aeruginosa: respective contributions of OprD and efflux systems. Antimicrob Agents Chemother 43 (1999) 424-427
19. Livermore D.M. Of Pseudomonas aeruginosa, porins, pumps, and carbapenems. J Antimicrob Chemother 47 (2001) 247-250
20. Masuda N., Sakagawa E., Ohya S., et al. Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-OprM efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother 44 (2000) 3322-3327
21. Carmeli Y., Troillet N., Eliopoulos G.M., et al. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 43 (1999) 1379-1382
22. Lucasti C., Jasovich A., Umeh O., et al. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study. Clin Ther 30 (2008) 868-883
23. Naber K., Redman R., Kotey P., et al. Intravenous therapy with doripenem versus levofloxacin with an option for oral step-down therapy in the treatment of complicated urinary tract infections and pyelonephritis. Int J Antimicrob Agents 29 Suppl 2 (2007) S212 [abstract form only]
24. Rea-Neto A., Niederman M., Lobo S.M., et al. Efficacy and safety of intravenous doripenem vs. piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study. Curr Med Res Opin 24 (2008) 2113-2126
25. Chastre J., Wunderink R., Prokocimer P., et al. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med 36 (2008) 1089-1096
26. Norrby S.R. Neurotoxicity of carbapenem antibacterials. Drug Saf 15 (1996) 87-90
27. Horiuchi M., Kimura M., Tokumura M., et al. Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with β-lactam antibiotics. Toxicology 222 (2006) 114-124
28. Chambers H.F. The changing epidemiology of Staphylococcus aureus?. Emerg Infect Dis 7 (2001) 178-182
29. Livermore D.M. Can beta-lactams be re-engineered to beat MRSA?. Clin Microbiol Infect 12 Suppl 2 (2006) 11-16
30. De Lecastre H., De Jonge B.L., Matthews P.R., et al. Molecular aspects of methicillin resistance in Staphylococcus aureus. J Antimicrob Chemother 33 (1994) 7-24
31. Anderson S.D., and Gums J.G. Ceftobiprole: an extended-spectrum anti-methicillin resistant Staphylococcus aureus cephalosporin. Ann Pharmacother 42 (2008) 806-816
32. Adis R&D profile. Ceftobiprole medocaril. Drugs R D 7 (2006) 305-311
33. Chambers H.F. Solving staphylococcal resistance to beta-lactams. Trends Microbiol 11 (2003) 145-148
34. Davies T.A., Page M.G., Shang W., et al. Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae. Antimicrob Agents Chemother 51 (2007) 2621-2624
35. Georgopapadakou N.H. Penicillin-binding proteins and bacterial resistance to β-lactams. Antimicrob Agents Chemother 37 (1993) 2045-2053
36. Wikipedia-free encyclopedia. Ceftobiprole. Available at:. http://en.wikipedia.org/wiki/ceftobiprole Accessed December 9, 2008
37. Murthy B., and Schmitt-Hoffman A. Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity. Clin Pharmacokinet 47 (2008) 21-33
38. Lodise T.P., Patel N., Renaud-Mutart A., et al. Pharmacokinetic and pharmacodynamic profile of ceftobiprole. Diagn Microbiol Infect Dis 61 (2008) 96-102
39. Lodise T.P., Pypstra R., Kahn J.B., et al. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects. Antimicrob Agents Chemother 51 (2007) 2378-2387
40. Mouton J.W., Schmitt-Hoffman A., Shapiro S., et al. Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141. Antimicrob Agents Chemother 48 (2004) 1713-1718
41. Noel G.J., Strauss R.S., Amsler K., et al. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob Agents Chemother 52 (2008) 37-44
42. Noel G.J., Bush K., Bagchi P., et al. A randomized double-blind trial comparing ceftobiprole medocaril to vancomycin plus ceftazidime in the treatment of patients with complicated skin and skin structure infections. Clin Infect Dis 46 (2008) 647-655
43. Fritsche T.R., Sader H.S., and Jones R.N. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY antimicrobial surveillance program (2005-2006). Diagn Microbiol Infect Dis 61 (2008) 86-95
44. Arias C.A., Singh K.V., Panesso D., et al. Time-kill and synergism studies of ceftobiprole against Enterococcus faecalis, including β-lactamase-producing and vancomycin-resistant isolates. Antimicrob Agents Chemother 51 (2007) 2043-2047
45. Goldstein E.J., Citron D.M., Merriam C.V., et al. In vitro activity of ceftobiprole against aerobic and anaerobic strains isolated from diabetic foot infections. Antimicrob Agents Chemother 50 (2006) 3959-3962
46. Queenan A.M., Shang W., Kania M., et al. Interactions of ceftobiprole with β-lactamases from molecular classes A to D. Antimicrob Agents Chemother 51 (2007) 3089-3095
47. Chambers H.F. Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 49 (2005) 884-888
48. Yin L.Y., Calhoun J.H., Thomas J.K., et al. Efficacies of ceftobiprole medocaril and comparators in a rabbit model of osteomyelitis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 52 (2008) 1618-1622
49. Laohavaleeson S., Tessier P.R., and Nicolau D.P. Pharmacodynamic characterization of ceftobiprole in experimental pneumonia caused by phenotypically diverse Staphylococcus aureus strains. Antimicrob Agents Chemother 52 (2008) 2389-2394
50. Ishikawa T., Matsunaga N., Tawada H., et al. TAK-599, a novel n-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties. Bioorg Med Chem 11 (2003) 2427-2437
51. Iizawa Y., Nagai J., Ishikawa T., et al. In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599. J Infect Chemother 10 (2004) 146-156
52. Andes D., and Craig W.A. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target. Antimicrob Agents Chemother 50 (2006) 1376-1383
53. Jacqueline C., Caillon J., Le Mabecque V., et al. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model. Antimicrob Agents Chemother 51 (2007) 3397-3400
54. Ge Y, Hubbel A. Poster.A-1935, 46th Intersci Conf Antimicrob Agents Chemother 2006.
55. Ge Y, Liao S, Talbot GH. Poster A-34, 47th Intersci Conf Antimicrob Agents Chemother 2007.
56. Ge Y, Liao S, Thye DA, et al. Poster A-35, 47th Intersci Conf Antimicrob Agents Chemother 2007.
57. Talbot G.H., Thye D., Das A., et al. Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 51 (2007) 3612-3616
58. Corey R, Wilcox M, Talbot GH, et al. Poster L-1515a, 48th Intersci Conf Antimicrob Agents Chemother/Infec Dis Soc Am 2008.
59. Sader H.S., Fritsche T.R., Kaniga K., et al. Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob Agents Chemother 49 (2005) 3501-3512
60. Ge Y., Biek D., Talbot G.H., et al. In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimicrob Agents Chemother 52 (2008) 3398-3407
61. Paul M., Yahav D., Fraser A., et al. Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 57 (2006) 176-189
62. Yahav D., Paul M., Fraser A., et al. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis 7 (2007) 338-348
63. B. Braun Medical Inc. Y36-002-592: cefepime for injection; proposed package insert. issued:xxx. Available at:. http://www.fda.gov/OHRMS/DOCKETS/dockets/06p0461/06p-0461-cp00001-04-attachment-03-vol1.pdf Accessed December 7, 2008
64. U.S. Food and Drug Administration. FDA drug warning. NDA 50-679/S-009, S-0014, and S-018.Available at:. http://www.fda.gov/cder/foi/appletter/2002/50679slr009,014,018ltr.pdf Accessed October 13, 2008
65. Bristol-Myers Squibb. Maxipime (cefepime) package insert (2007), Bristol-Myers Squibb, Princeton (NJ)
66. Sanders C.C. Cefepime: the next generation?. Clin Infect Dis 17 (1993) 369-379
67. Sanders Jr. W.E., Tenney J.H., and Kessler R.E. Efficacy of cefepime in the treatment of infections due to multiply resistant Enterobacter species. Clin Infect Dis 23 (1996) 454-461
68. Acar J. Rapid emergence of resistance to cefepime during treatment. Clin Infect Dis 26 (1998) 1484-1486
69. Wynd M.A., and Paladino J.A. Cefepime: a fourth generation parenteral cephalosporin. Ann Pharmacother 30 (1996) 1414-1424
70. Kessler R.E., Bies M., Buck R.E., et al. Comparison of a new cephalosporin, BMY-28142, with other broad spectrum beta-lactam antibiotics. Antimicrob Agents Chemother 27 (1985) 207-216
71. Conrad D.A., Scribner R.K., Weber A.H., et al. In vitro activity of BMY-28142 against pediatric pathogens, including isolates from cystic fibrosis sputum. Antimicrob Agents Chemother 28 (1985) 58-63
72. Neu H.C. Safety of cefepime: a new extended-spectrum parenteral cephalosporin. Am J Med 100 6A (1996) 68S-75S
73. Pichichero M.E. Use of selected cephalosporins in penicillin-allergic patients: a paradigm shift. Diagn Microbiol Infect Dis 57 Suppl 3 (2007) S13-S18
74. Martin S.I., and Kaye K.M. Beta-lactam antibiotics: newer formulations and newer agents. Infect Dis Clin North Am 18 (2004) 603-619
75. U.S. Food and Drug Administration. Early communication about ongoing safety review: cefepime (marketed as Maxipime). Available at:. http://www.fda.gov/cder/drug/early_comm/cefepime.htm Accessed October 19, 2008
76. U.S. Food and Drug Administration. Update of safety review: follow-up to the November 14, 2007, communication about the ongoing safety review of cefepime (marketed as Maxipime). Available at:. http://www.fda.gov/cder/drug/early_comm/cefepime_update_200805.htm Accessed October 19, 2008
77. U.S. Food and Drug Administration. FDA Alert June 17, 2009; Information for Healthcare Professionals: Cefepime (marketed as Maxipime). Available at:. http://www.fda.gov/drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugsSafetyInformationforHealthcareProfessionals/ucm167254.htm Accessed July 27, 2009